These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 23339926)
1. Identification of a synthetic muramyl peptide derivative with enhanced Nod2 stimulatory capacity. Rubino SJ; Magalhaes JG; Philpott D; Bahr GM; Blanot D; Girardin SE Innate Immun; 2013 Oct; 19(5):493-503. PubMed ID: 23339926 [TBL] [Abstract][Full Text] [Related]
2. Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Magalhaes JG; Lee J; Geddes K; Rubino S; Philpott DJ; Girardin SE Eur J Immunol; 2011 May; 41(5):1445-55. PubMed ID: 21469090 [TBL] [Abstract][Full Text] [Related]
3. Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn's associated NOD2 gene variants. Salem M; Seidelin JB; Eickhardt S; Alhede M; Rogler G; Nielsen OH Clin Exp Immunol; 2015 Mar; 179(3):426-34. PubMed ID: 25335775 [TBL] [Abstract][Full Text] [Related]
4. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Maeda S; Hsu LC; Liu H; Bankston LA; Iimura M; Kagnoff MF; Eckmann L; Karin M Science; 2005 Feb; 307(5710):734-8. PubMed ID: 15692052 [TBL] [Abstract][Full Text] [Related]
5. Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. Coulombe F; Divangahi M; Veyrier F; de Léséleuc L; Gleason JL; Yang Y; Kelliher MA; Pandey AK; Sassetti CM; Reed MB; Behr MA J Exp Med; 2009 Aug; 206(8):1709-16. PubMed ID: 19581406 [TBL] [Abstract][Full Text] [Related]
6. hPepT1 selectively transports muramyl dipeptide but not Nod1-activating muramyl peptides. Ismair MG; Vavricka SR; Kullak-Ublick GA; Fried M; Mengin-Lecreulx D; Girardin SE Can J Physiol Pharmacol; 2006 Dec; 84(12):1313-9. PubMed ID: 17487240 [TBL] [Abstract][Full Text] [Related]
7. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Li J; Moran T; Swanson E; Julian C; Harris J; Bonen DK; Hedl M; Nicolae DL; Abraham C; Cho JH Hum Mol Genet; 2004 Aug; 13(16):1715-25. PubMed ID: 15198989 [TBL] [Abstract][Full Text] [Related]
8. The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also Nod1-activating peptidoglycan agonists. Netea MG; Ferwerda G; de Jong DJ; Werts C; Boneca IG; Jéhanno M; Van Der Meer JW; Mengin-Lecreulx D; Sansonetti PJ; Philpott DJ; Dharancy S; Girardin SE J Biol Chem; 2005 Oct; 280(43):35859-67. PubMed ID: 16115863 [TBL] [Abstract][Full Text] [Related]
9. Innate immune sensing of microbes by Nod proteins. Kufer TA; Banks DJ; Philpott DJ Ann N Y Acad Sci; 2006 Aug; 1072():19-27. PubMed ID: 17057187 [TBL] [Abstract][Full Text] [Related]
10. The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype. Borm ME; van Bodegraven AA; Mulder CJ; Kraal G; Bouma G Genes Immun; 2008 Apr; 9(3):274-8. PubMed ID: 18340358 [TBL] [Abstract][Full Text] [Related]
11. Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease. van Heel DA; Hunt KA; Ghosh S; Hervé M; Playford RJ Eur J Immunol; 2006 Jun; 36(6):1629-35. PubMed ID: 16637007 [TBL] [Abstract][Full Text] [Related]
13. NOD2 modulates immune tolerance via the GM-CSF-dependent generation of CD103 Prescott D; Maisonneuve C; Yadav J; Rubino SJ; Girardin SE; Philpott DJ Proc Natl Acad Sci U S A; 2020 May; 117(20):10946-10957. PubMed ID: 32350141 [TBL] [Abstract][Full Text] [Related]
14. Genome-wide expression profiling identifies an impairment of negative feedback signals in the Crohn's disease-associated NOD2 variant L1007fsinsC. Billmann-Born S; Till A; Arlt A; Lipinski S; Sina C; Latiano A; Annese V; Häsler R; Kerick M; Manke T; Seegert D; Hanidu A; Schäfer H; van Heel D; Li J; Schreiber S; Rosenstiel P J Immunol; 2011 Apr; 186(7):4027-38. PubMed ID: 21335489 [TBL] [Abstract][Full Text] [Related]
15. A synthetic NOD2 agonist, muramyl dipeptide (MDP)-Lys (L18) and IFN-β synergistically induce dendritic cell maturation with augmented IL-12 production and suppress melanoma growth. Fujimura T; Yamasaki K; Hidaka T; Ito Y; Aiba S J Dermatol Sci; 2011 May; 62(2):107-15. PubMed ID: 21411292 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of Muramyl Dipeptide-Dependent NOD2 Activity by a Self-Derived Peptide. Mann JK; Shen J; Park S J Cell Biochem; 2017 May; 118(5):1227-1238. PubMed ID: 27791288 [TBL] [Abstract][Full Text] [Related]
17. Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice. Dugan J; Griffiths E; Snow P; Rosenzweig H; Lee E; Brown B; Carr DW; Rose C; Rosenbaum J; Davey MP J Immunol; 2015 Jan; 194(1):349-57. PubMed ID: 25429073 [TBL] [Abstract][Full Text] [Related]
18. Engagement of NOD2 has a dual effect on proIL-1beta mRNA transcription and secretion of bioactive IL-1beta. Ferwerda G; Kramer M; de Jong D; Piccini A; Joosten LA; Devesaginer I; Girardin SE; Adema GJ; van der Meer JW; Kullberg BJ; Rubartelli A; Netea MG Eur J Immunol; 2008 Jan; 38(1):184-91. PubMed ID: 18157816 [TBL] [Abstract][Full Text] [Related]
19. Nod2-dependent Th2 polarization of antigen-specific immunity. Magalhaes JG; Fritz JH; Le Bourhis L; Sellge G; Travassos LH; Selvanantham T; Girardin SE; Gommerman JL; Philpott DJ J Immunol; 2008 Dec; 181(11):7925-35. PubMed ID: 19017983 [TBL] [Abstract][Full Text] [Related]